386 related articles for article (PubMed ID: 12573431)
1. Neurofibromatosis 1: closing the GAP between mice and men.
Dasgupta B; Gutmann DH
Curr Opin Genet Dev; 2003 Feb; 13(1):20-7. PubMed ID: 12573431
[TBL] [Abstract][Full Text] [Related]
2. Neurofibromatosis type 1 (NF1) tumor suppressor, neurofibromin, regulates the neuronal differentiation of PC12 cells via its associating protein, CRMP-2.
Patrakitkomjorn S; Kobayashi D; Morikawa T; Wilson MM; Tsubota N; Irie A; Ozawa T; Aoki M; Arimura N; Kaibuchi K; Saya H; Araki N
J Biol Chem; 2008 Apr; 283(14):9399-413. PubMed ID: 18218617
[TBL] [Abstract][Full Text] [Related]
3. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.
Ratner N; Miller SJ
Nat Rev Cancer; 2015 May; 15(5):290-301. PubMed ID: 25877329
[TBL] [Abstract][Full Text] [Related]
4. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes.
Dasgupta B; Dugan LL; Gutmann DH
J Neurosci; 2003 Oct; 23(26):8949-54. PubMed ID: 14523097
[TBL] [Abstract][Full Text] [Related]
5. Cardiomyocyte-specific loss of neurofibromin promotes cardiac hypertrophy and dysfunction.
Xu J; Ismat FA; Wang T; Lu MM; Antonucci N; Epstein JA
Circ Res; 2009 Jul; 105(3):304-11. PubMed ID: 19574548
[TBL] [Abstract][Full Text] [Related]
6. Interaction between a Domain of the Negative Regulator of the Ras-ERK Pathway, SPRED1 Protein, and the GTPase-activating Protein-related Domain of Neurofibromin Is Implicated in Legius Syndrome and Neurofibromatosis Type 1.
Hirata Y; Brems H; Suzuki M; Kanamori M; Okada M; Morita R; Llano-Rivas I; Ose T; Messiaen L; Legius E; Yoshimura A
J Biol Chem; 2016 Feb; 291(7):3124-34. PubMed ID: 26635368
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of activation of the tumor suppressor protein neurofibromin.
Chaker-Margot M; Werten S; Dunzendorfer-Matt T; Lechner S; Ruepp A; Scheffzek K; Maier T
Mol Cell; 2022 Apr; 82(7):1288-1296.e5. PubMed ID: 35353986
[TBL] [Abstract][Full Text] [Related]
8. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.
Lau N; Feldkamp MM; Roncari L; Loehr AH; Shannon P; Gutmann DH; Guha A
J Neuropathol Exp Neurol; 2000 Sep; 59(9):759-67. PubMed ID: 11005256
[TBL] [Abstract][Full Text] [Related]
9. Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning.
Anastasaki C; Woo AS; Messiaen LM; Gutmann DH
Hum Mol Genet; 2015 Jun; 24(12):3518-28. PubMed ID: 25788518
[TBL] [Abstract][Full Text] [Related]
10. Physical interaction between neurofibromin and serotonin 5-HT6 receptor promotes receptor constitutive activity.
Deraredj Nadim W; Chaumont-Dubel S; Madouri F; Cobret L; De Tauzia ML; Zajdel P; Bénédetti H; Marin P; Morisset-Lopez S
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):12310-12315. PubMed ID: 27791021
[TBL] [Abstract][Full Text] [Related]
11. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes.
Dasgupta B; Li W; Perry A; Gutmann DH
Cancer Res; 2005 Jan; 65(1):236-45. PubMed ID: 15665300
[TBL] [Abstract][Full Text] [Related]
12. Neurofibromin Deficiency Causes Epidermal Growth Factor Receptor Upregulation through the Activation of Ras/ERK/SP1 Signaling Pathway in Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheet Tumor.
Park GH; Lee SJ; Lee CG; Kim J; Park E; Jeong SY
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948100
[TBL] [Abstract][Full Text] [Related]
13. Reconstitution of the NF1 GAP-related domain in NF1-deficient human Schwann cells.
Thomas SL; Deadwyler GD; Tang J; Stubbs EB; Muir D; Hiatt KK; Clapp DW; De Vries GH
Biochem Biophys Res Commun; 2006 Sep; 348(3):971-80. PubMed ID: 16908010
[TBL] [Abstract][Full Text] [Related]
14. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
15. Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1.
Klose A; Ahmadian MR; Schuelke M; Scheffzek K; Hoffmeyer S; Gewies A; Schmitz F; Kaufmann D; Peters H; Wittinghofer A; Nürnberg P
Hum Mol Genet; 1998 Aug; 7(8):1261-8. PubMed ID: 9668168
[TBL] [Abstract][Full Text] [Related]
16. Ras-Mek-Erk signaling regulates Nf1 heterozygous neointima formation.
Stansfield BK; Bessler WK; Mali R; Mund JA; Downing BD; Kapur R; Ingram DA
Am J Pathol; 2014 Jan; 184(1):79-85. PubMed ID: 24211110
[TBL] [Abstract][Full Text] [Related]
17. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.
Dilworth JT; Kraniak JM; Wojtkowiak JW; Gibbs RA; Borch RF; Tainsky MA; Reiners JJ; Mattingly RR
Biochem Pharmacol; 2006 Nov; 72(11):1485-92. PubMed ID: 16797490
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.
Dasgupta B; Yi Y; Chen DY; Weber JD; Gutmann DH
Cancer Res; 2005 Apr; 65(7):2755-60. PubMed ID: 15805275
[TBL] [Abstract][Full Text] [Related]
19. A novel diagnostic method to detect truncated neurofibromin in neurofibromatosis 1.
Esposito T; Piluso G; Saracino D; Uccello R; Schettino C; Dato C; Capaldo G; Giugliano T; Varriale B; Paolisso G; Di Iorio G; Melone MA
J Neurochem; 2015 Dec; 135(6):1123-8. PubMed ID: 26478990
[TBL] [Abstract][Full Text] [Related]
20. Neurofibromatosis-1 heterozygosity impairs CNS neuronal morphology in a cAMP/PKA/ROCK-dependent manner.
Brown JA; Diggs-Andrews KA; Gianino SM; Gutmann DH
Mol Cell Neurosci; 2012 Jan; 49(1):13-22. PubMed ID: 21903164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
